Patient characteristics and 6‐month dose of basal insulin associated with HbA1c achievement <7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment (ORBIT)

Background The efficacy of basal insulin (BI) for adequate glycemic control in patients with type 2 diabetes mellitus (T2DM) has been well documented by randomized clinical trials. This post hoc analysis of the Observational Registry of Basal Insulin Treatment (ORBIT) study was performed to explore...

Full description

Saved in:
Bibliographic Details
Published in:Journal of diabetes 2020-09, Vol.12 (9), p.668-676
Main Authors: Gao, Leili, Zhang, Puhong, Weng, Jianping, Lu, Juming, Guo, Xiaohui, Jia, Weiping, Yang, Wenying, Zou, Dajin, Zhou, Zhiguang, Pan, Changyu, Gao, Yan, Li, Xian, Zhu, Dongshan, Wu, Yangfeng, Garg, Satish K., Ji, Linong
Format: Article
Language:English
Subjects:
6‐month dose
6个月时的剂量
Antidiabetics
basal insulin
China
Diabetes
Disease management
Glucose
HbA1c
Hemoglobin
Insulin
Patients
中国
基础胰岛素
糖化血红蛋白
糖尿病
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The efficacy of basal insulin (BI) for adequate glycemic control in patients with type 2 diabetes mellitus (T2DM) has been well documented by randomized clinical trials. This post hoc analysis of the Observational Registry of Basal Insulin Treatment (ORBIT) study was performed to explore the 6‐month dose of BI used in insulin‐naïve T2DM patients achieving HbA1c target (
ISSN:1753-0393
1753-0407
DOI:10.1111/1753-0407.13046